Benzinga - Gainers
- Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
- Core Scientific, Inc. (NASDAQ: CORZ) rose 65% to $0.4125. B. Riley Financial issued an open letter to Core Scientific shareholders and lenders.
- Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 58.1% to $0.3711 after declining 4% on Wednesday.
- Icosavax, Inc. (NASDAQ: ICVX) shares climbed 42.9% to $12.75. Icosavax shares jumped 112% on Wednesday after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus
- IMV Inc. (NASDAQ: IMV) surged 34.4% to $2.89 after the company announced initial data from the ongoing Phase 2B VITALIZE trial in patients with r/r DLBCL.
- Clearmind Medicine Inc. (NASDAQ: CMND) shares jumped 22.3% to $3.8898. Clearmind Medicine’s CEO, Dr. Adi Zuloff-Shani, issued a letter to shareholders.
- Kintara Therapeutics, Inc. (NASDAQ: KTRA) rose 18.8% to $9.52. Kintara Therapeutics received orphan drug designation for VAL-083 for treatment of diffuse intrinsic pontine glioma.
- Lanvin Group Holdings Ltd. (NYSE: LANV) gained 18% to $11.75.
- Iterum Therapeutics plc (NASDAQ: ITRM) surged 18% to $1.34 after the company announced issuance of allowance for a U.S. patent covering oral sulopenem.
- Troika Media Group, Inc. (NASDAQ: TRKA) gained 17% to $0.12.
- Astria Therapeutics, Inc. (NASDAQ: ATXS) rose 15.8% to $12.76. Astria Therapeutics announced preliminary results from the Phase 1a trial of STAR-0215 in healthy subjects.
- Steakholder Foods Ltd. (NASDAQ: STKH) rose 15% to $0.89.
- Rallybio Corporation (NASDAQ: RLYB) surged 14.1% to $7.20. Rallybio announced publication of data highlighting the ability of HPA-1a-specific antibodies to prevent alloimmunization in an authentic mouse model of FNAIT.
- Surrozen, Inc. (NASDAQ: SRZN) shares gained 12.6% to $0.4907. The company, last month, posted a narrower Q3 loss.
- Agilysys, Inc. (NASDAQ: AGYS) jumped 9.7% to $67.79.
- Blue Apron Holdings, Inc. (NYSE: APRN) rose 9% to $0.7020 after the company provided an update on funding from Mr. Joseph Sanberg's affiliates. Blue Apron said it received $1 million of the private placement obligation.
- Sio Gene Therapies Inc (NASDAQ: SIOX) rose 8.8% to $0.3901. On December 14, 2022, the company’s board unanimously approved the dissolution and liquidation of the company pursuant to a plan of complete liquidation and dissolution.
- Carvana Co. (NYSE: CVNA) gained 8.8% to $5.72. Carvana started offering as-soon-as-next-day touchless home delivery to Corvallis, Oregon, area residents.
- RCI Hospitality Holdings, Inc. (NASDAQ: RICK) jumped 7.6% to $93.73 folloiwng better-than-expected Q4 results.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers
- Third Harmonic Bio, Inc. (NASDAQ: THRD) shares tumbled 78.3% to $4.3090 after the company announced discontinuation of its Phase 1b study of THB001 in chronic inducible urticaria.
- Miromatrix Medical Inc. (NASDAQ: MIRO) fell 29.3% to $2.8997. The FDA has placed a clinical hold on Miromatrix Medical’s miroliverELAP Investigational New Drug (IND) application for acute liver failure.
- Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell 20.4% to $0.0948. Panbela recently received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
- Novavax, Inc. (NASDAQ: NVAX) shares fell 19.8% to $13.81. Novavax proposed an underwritten public offering to sell up to $125 million of its common stock.
- MicroAlgo Inc. (NASDAQ: MLGO) declined 19.8% to $2.4050.
- Axcella Health Inc. (NASDAQ: AXLA) dropped 19.3% to $0.72. Axcella Health announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.
- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) fell 19% to $0.4170. Vallon Pharmaceuticals shares jumped around 105% on Wednesday after the company and GRI Bio announced they entered into a merger agreement.
- MicroAlgo Inc. (NASDAQ: MLGO) fell 19% to $2.43.
- Drive Shack Inc. (NYSE: DS) shares fell 16.6% to $0.2001. Drive Shack shares dropped around 50% on Wednesday after the company announced the intention to voluntarily delist and deregister its securities.
- Meiwu Technology Company Limited (NASDAQ: WNW) fell 16.5% to $2.1708 after surging 41% on Wednesday.
- Roblox Corporation (NASDAQ: RBLX) dropped 15.2% to $28.08 after the company reported November 2022 key metrics.
- Verve Therapeutics, Inc. (NASDAQ: VERV) fell 12.9% to $19.69 after Goldman Sachs (NYSE:GS) initiated coverage on the stock with a Sell rating and announced a $13 price target.
- Elys Game Technology, Corp. (NASDAQ: ELYS) declined 11.6% to $0.1630.
- BIMI International Medical, Inc. (NASDAQ: BIMI) fell 10.7% to $2.5263 after climbing 36% on Wednesday. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
- HUYA Inc. (NYSE: HUYA) dropped 10.7% to $3.00.
- Alight, Inc. (NYSE: ALIT) fell 10.6% to $8.02. Alight, last week, announced the acquisition of ReedGroup.
- Indaptus Therapeutics, Inc. (NASDAQ: INDP) declined 10.3% to $1.5601.
- Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) fell 10.2% to $4.33. Checkpoint Therapeutics announced a $7.5 million registered direct offering priced at-the-market under Nasdaq rules.
- Shore Bancshares, Inc. (NASDAQ: SHBI) declined 8.3% to $17.47. Shore Bancshares and The Community Financial Corporation announced merger of equals to create bank with $6 billion in assets.x
- NantHealth, Inc. (NASDAQ: NH) dropped 8.6% to $0.2150. NantHealth announced a 1-for-15 reverse stock split.
- GlycoMimetics, Inc. (NASDAQ: GLYC) shares fell 8.5% to $2.0213.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.